Doctors Note Logo

Published on: 9/23/2026

Who is recommended for the RSV vaccine at age 50 to 74?

Adults ages 50 to 74 are recommended for a single dose of RSV vaccine if they have conditions that raise their risk of severe RSV illness, such as chronic heart or lung disease, diabetes with organ damage, kidney or liver disease, weakened immune systems, severe obesity, certain neurologic conditions, or living in a nursing home. Eligibility depends on your specific risk factors, vaccine type, and whether you have already received an RSV vaccine, so see below for the full details before deciding. If you are currently coughing, wheezing, short of breath, or feeling feverish, the next step is figuring out whether your symptoms point to RSV, flu, COVID-19, or something else entirely. A free, instant symptom check can help you understand what may be causing your symptoms and what level of care to seek. It takes only a few minutes, is available any time, and gives you clearer questions to bring to your doctor or pharmacist about vaccination and treatment.

Last reviewed for medical accuracy: 09/23/2025

answer background

Explanation

Who Should Get RSV Vaccine at Age 50 to 74?

Respiratory syncytial virus (RSV) is a common respiratory virus that can cause serious lung and breathing problems—especially in older adults. In 2023, two RSV vaccines (Abrysvo and Arexvy) were approved in the U.S. for older adults. Understanding who should get RSV vaccine and when can help you make an informed decision about protecting yourself.

Why Consider RSV Vaccination?

  • RSV spreads easily through coughs, sneezes or direct contact with contaminated surfaces.
  • While it often causes mild, cold-like symptoms, RSV can lead to severe illness such as pneumonia or bronchiolitis.
  • Adults aged 50 and older begin to lose some of their natural immune protection, raising the risk of complications.
  • Vaccination is a proactive way to lower your chances of hospitalization and serious respiratory illness.

Who Should Get RSV Vaccine?

Adults Aged 60–74

According to recommendations from the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP):

  • All adults 60 through 74 years of age should receive a one-time RSV vaccine to reduce the risk of severe RSV disease.
  • There is no requirement for underlying health conditions in this age group—age alone is sufficient reason.

Adults Aged 50–59 with Underlying Medical Conditions

The U.S. Food and Drug Administration (FDA) has approved RSV vaccination for adults 50 through 59 years who are at increased risk of severe RSV infection due to:

  • Chronic lung disease (including asthma, chronic obstructive pulmonary disease)
  • Cardiovascular disease (heart failure, coronary artery disease)
  • Diabetes (type 1 or type 2)
  • Kidney disorder or chronic kidney disease
  • Liver disorder (cirrhosis, hepatitis)
  • Hematologic disorders (sickle cell disease, thalassemia)
  • Weakened immune system (due to cancer treatments, HIV infection, organ transplant)
  • Neurologic or neuromuscular conditions that impair coughing or breathing
  • Obesity (body mass index ≥ 30 kg/m²)
  • Smoking (current or former)

If you fall into any of these categories and are 50 through 59, talk to your health care provider about getting the RSV vaccine as soon as it’s available to you.

Who May Consider RSV Vaccine Even Without High-Risk Conditions?

If you are 50–59 but do not have one of the high-risk conditions above, you might still consider vaccination if:

  • You live with or care for older adults (to help prevent spreading RSV).
  • You are a daily smoker or have significant secondhand smoke exposure.
  • You frequently travel or are in group settings where respiratory infections spread easily (cruise ships, shelters, care homes).

These factors can elevate your chance of catching and transmitting RSV, so a chat with your doctor can help you decide if vaccination is right for you.

Timing and Dosage

  • Single Dose: Both Abrysvo and Arexvy are given as a one-time intramuscular injection.
  • Best Time to Get Vaccinated: Aim for vaccination before RSV season begins in your area (often fall through early winter).
  • No Repeat Dose Yet Recommended: Current guidance calls for just one dose; future research may update this.

Potential Side Effects

Most people tolerate RSV vaccines well. Common side effects may include:

  • Soreness, redness or swelling at the injection site
  • Fatigue or muscle aches
  • Headache
  • Fever (low-grade) or chills

These reactions are generally mild and go away within a few days. Serious side effects are rare. Always report any unexpected or severe symptoms to your health care provider.

Benefits vs. Risks

  • Benefit: Significantly lowers risk of severe RSV disease, hospitalization and complications
  • Low Risk: Mild, short-lived side effects are most commonly reported

By weighing the relatively minor risks of side effects against the potential for severe respiratory illness, most experts agree that vaccination is the safer choice.

Steps to Take

  1. Assess Your Eligibility

    • Are you 60–74? You are recommended to get a single dose.
    • Are you 50–59 with one or more high-risk conditions? Discuss vaccination with your doctor.
  2. Find a Vaccination Site

    • Many pharmacies, clinics and primary care offices offer RSV vaccines.
    • Your health insurer’s website can help you locate covered providers.
  3. Prepare for Your Visit

    • Bring your photo ID and insurance card.
    • Share your health history, including chronic conditions and medications.
  4. Plan for Mild Side Effects

    • Schedule vaccination at a time when you can rest if you feel achy.
    • Stay hydrated and use over-the-counter pain relievers (as advised by your doctor) if needed.

Monitoring Your Health

Even if you feel fine after vaccination, it’s wise to stay alert for any respiratory symptoms. If you develop cough, fever, shortness of breath or wheezing:

  • Perform a free, online symptom check, using the doctor approved Ubie Symptom Checker
  • Keep track of symptom progression and share details with your health care provider
  • Seek medical attention promptly if you experience chest pain, difficulty breathing, confusion or persistent high fever

Speak to a Doctor

Your personal health situation is unique. Although broad recommendations exist, only your doctor can:

  • Confirm you fall into the right age and risk categories
  • Advise on timing relative to other vaccines (flu, COVID-19 boosters)
  • Discuss any potential interactions with current medications
  • Address concerns about vaccine safety and side effects

If you experience any life-threatening or serious symptoms—chest pain, severe shortness of breath, sudden dizziness—seek emergency medical care right away.


Getting the RSV vaccine is a straightforward, effective step toward protecting your respiratory health as you age. By knowing who should get RSV vaccine and taking action at the right time, you can lower your risk of severe illness and stay healthier through RSV season and beyond.

(References)

  • * Chu HY, Englund JA. Maternal immunization. Birth Defects Res. 2017 Mar 15;109(5):379-386. doi: 10.1002/bdra.23547. PMID: 28398678.

  • * Lichscheidt ED, Harboe ZB, Fischer TK, Larsen CS. Vaccines against respiratory syncytial virus. Ugeskr Laeger. 2024 Mar 11;186(11). doi: 10.61409/V12230800. PMID: 38533866.

  • * Britton A, Roper LE, Kotton CN, Hutton DW, Fleming-Dutra KE, Godfrey M, Ortega-Sanchez IR, Broder KR, Talbot HK, Long SS, Havers FP, Melgar M. Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2024. MMWR Morb Mortal Wkly Rep. 2024 Aug 15;73(32):696-702. doi: 10.15585/mmwr.mm7332e1. Epub 2024 Aug 15. PMID: 39146277.

  • * Payne AB, Watts JA, Mitchell PK, Dascomb K, Irving SA, Klein NP, Grannis SJ, Ong TC, Ball SW, DeSilva MB, Natarajan K, Sheffield T, Bride D, Arndorfer J, Naleway AL, Koppolu P, Fireman B, Zerbo O, Timbol J, Goddard K, Dixon BE, Fadel WF, Rogerson C, Allen KS, Rao S, Mayer D, Barron M, Reese SE, Rowley EAK, Najdowski M, Ciesla AA, Mak J, Reeves EL, Akinsete OO, McEvoy CE, Essien IJ, Tenforde MW, Fleming-Dutra KE, Link-Gelles R. Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis. Lancet. 2024 Oct 19;404(10462):1547-1559. doi: 10.1016/S0140-6736(24)01738-0. PMID: 39426837; PMCID: PMC13286031.

  • * Duan Y, Liu Z, Zang N, Cong B, Shi Y, Xu L, Jiang M, Wang P, Zou J, Zhang H, Feng Z, Feng L, Ren L, Liu E, Li Y, Zhang Y, Xie Z. Landscape of respiratory syncytial virus. Chin Med J (Engl). 2024 Dec 20;137(24):2953-2978. doi: 10.1097/CM9.0000000000003354. Epub 2024 Nov 6. PMID: 39501814; PMCID: PMC11706595.

  • * Moline HL, Toepfer AP, Tannis A, Weinberg GA, Staat MA, Halasa NB, Boom JA, Klein EJ, Williams JV, Schuster JE, Goldstein L, McKeever ER, Kalman C, Paden C, Atherton L, Aggarwal M, Roychoudhury P, Piedra PA, Sahni LC, Stewart LS, Selvarangan R, Michaels MG, Schlaudecker EP, Szilagyi PG, Englund JA, Clopper BR, Thornburg NJ, Derado G, McMorrow ML, Dawood FS, New Vaccine Surveillance Network Collaborators. Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024. JAMA Pediatr. 2025 Feb 1;179(2):179-187. doi: 10.1001/jamapediatrics.2024.5572. PMID: 39652359; PMCID: PMC11667569.

  • * Anastassopoulou C, Medić S, Ferous S, Boufidou F, Tsakris A. Development, Current Status, and Remaining Challenges for Respiratory Syncytial Virus Vaccines. Vaccines (Basel). 2025 Jan 21;13(2). doi: 10.3390/vaccines13020097. Epub 2025 Jan 21. PMID: 40006644; PMCID: PMC11860200.

  • * Foley DA, Phuong LK. RSV: an update on prevention and management. Aust Prescr. 2025 Apr;48(2):34-39. doi: 10.18773/austprescr.2025.018. PMID: 40343137; PMCID: PMC12055488.

  • * Surie D, Self WH, Yuengling KA, Lauring AS, Zhu Y, Safdar B, Ginde AA, Simon SJ, Peltan ID, Brown SM, Gaglani M, Ghamande S, Columbus C, Mohr NM, Gibbs KW, Hager DN, Prekker M, Gong MN, Mohamed A, Johnson NJ, Steingrub JS, Khan A, Duggal A, Gordon AJ, Qadir N, Chang SY, Mallow C, Felzer JR, Kwon JH, Exline MC, Vaughn IA, Ramesh M, Papalambros L, Mosier JM, Harris ES, Baughman A, Cornelison SA, Blair PW, Johnson CA, Lewis NM, Ellington S, Grijalva CG, Talbot HK, Casey JD, Halasa N, Chappell JD, Rutkowski RE, Ma KC, Dawood FS, Investigating Respiratory Viruses in the Acutely Ill (IVY) Network. RSV Vaccine Effectiveness Against Hospitalization Among US Adults Aged 60 Years or Older During 2 Seasons. JAMA. 2025 Oct 28;334(16):1442-1451. doi: 10.1001/jama.2025.15896. PMID: 40884491; PMCID: PMC12398767.

  • * Scott J, Abers MS, Marwah HK, McCann NC, Meyerowitz EA, Richterman A, Fleming DF, Holmes EJ, Moat LE, Redepenning SG, Smith EA, Stoddart CJ, Sundaram ME, Ulrich AK, Alba C, Anderson CJ, Arpey MK, Borre E, Ladines-Lim J, Mehr AJ, Rich K, Watts C, Basta NE, Jarolimova J, Walensky RP, Dugdale CM. Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025-2026. N Engl J Med. 2025 Dec 4;393(22):2221-2242. doi: 10.1056/NEJMsa2514268. Epub 2025 Oct 29. PMID: 41160817.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.